Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research note released on Monday morning, Benzinga reports. The brokerage currently has a $7.00 price objective on the stock. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ FY2026 earnings at $0.06 EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.18 EPS.

Separately, Cantor Fitzgerald reissued an overweight rating and set a $6.00 price objective on shares of Lineage Cell Therapeutics in a report on Monday, February 5th.

Lineage Cell Therapeutics Stock Performance

Shares of LCTX stock opened at $1.18 on Monday. The firm has a market cap of $222.78 million, a PE ratio of -9.08 and a beta of 1.39. Lineage Cell Therapeutics has a 12-month low of $0.84 and a 12-month high of $1.61.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. The firm had revenue of $2.09 million for the quarter, compared to analyst estimates of $4.74 million. Lineage Cell Therapeutics had a negative net margin of 240.20% and a negative return on equity of 31.95%. On average, analysts predict that Lineage Cell Therapeutics will post -0.13 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC lifted its stake in Lineage Cell Therapeutics by 61.6% in the 4th quarter. SG Americas Securities LLC now owns 30,889 shares of the company’s stock valued at $34,000 after buying an additional 11,779 shares in the last quarter. DCF Advisers LLC raised its holdings in Lineage Cell Therapeutics by 14.5% in the 4th quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock valued at $103,000 after acquiring an additional 12,000 shares during the last quarter. Fifth Third Wealth Advisors LLC acquired a new stake in Lineage Cell Therapeutics in the 1st quarter valued at about $30,000. Finally, Rathbones Group PLC acquired a new stake in Lineage Cell Therapeutics in the 3rd quarter valued at about $41,000. 62.47% of the stock is owned by hedge funds and other institutional investors.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.